Figure 1.

CCL5 treatment activates the mTOR/AKT pathway in breast cancer cells. (a) Cells were either left untreated, treated with 10 nM CCL5 for the indicated times or pre-treated with 2uM TAK-779 for 1 h prior to CCL5 treatment. Cell lysates were prepared and resolved by SDS-PAGE, and then immunoblotted with the indicated antibodies. Data shown are representative of three independent experiments. (b) Bands were quantified by densitometry using ImageJ software and normalized relative to the corresponding unphosphorylated proteins. Bar graphs represent means ± s.e. of the combined data from the three experiments. Statistical analysis was performed comparing different treatments: *p < 0.05, **p < 0.01 and ***p < 0.001.